Predicted protein targets (top 17)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | SMN1; SMN2 | Q16637 | 1/20 | 0.50 |
| ▸ | MAPK1 | P28482 | 1/20 | 0.45 |
| ▸ | GAA | P10253 | 1/20 | 0.45 |
| ▸ | GRM2 | Q14416 | 1/20 | 0.44 |
| ▸ | FKBP1A | P62942 | 1/20 | 0.43 |
| ▸ | TSHR | P16473 | 1/20 | 0.43 |
| ▸ | HIF1A | Q16665 | 1/20 | 0.43 |
| ▸ | EPAS1 | Q99814 | 1/20 | 0.43 |
| ▸ | POLB | P06746 | 1/20 | 0.42 |
| ▸ | MMP1 | P03956 | 1/20 | 0.42 |
| ▸ | MMP13 | P45452 | 1/20 | 0.42 |
| ▸ | KDM4E | B2RXH2 | 1/20 | 0.42 |
| ▸ | CMA1 | P23946 | 1/20 | 0.41 |
| ▸ | PDE1A | P54750 | 3/20 | 0.41 |
| ▸ | PDE1B | Q01064 | 3/20 | 0.41 |
| ▸ | PDE1C | Q14123 | 3/20 | 0.41 |
| ▸ | CYP19A1 | P11511 | 1/20 | 0.40 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL13547190 | 1.00 | SMN1; SMN2 (0.50) | SMN1; SMN2MAPK1GAAGRM2FKBP1A | |
| SCHEMBL3618418 | 0.86 | MAPK1 (0.47) | SMN1; SMN2MAPK1GAAFKBP1ATSHR | |
| SCHEMBL3618274 | 0.86 | MAPK1 (0.47) | SMN1; SMN2MAPK1GAAFKBP1ATSHR | |
| SCHEMBL14172059 | 0.85 | HDAC1 (0.43) | MAPK1GAATSHRPOLBKDM4E | |
| SCHEMBL3610793 | 0.82 | SMN1; SMN2 (0.52) | SMN1; SMN2MAPK1GAAGRM2FKBP1A | |
| SCHEMBL3611571 | 0.82 | SMN1; SMN2 (0.52) | SMN1; SMN2MAPK1GAAGRM2FKBP1A | |
| SCHEMBL14172061 | 0.82 | GRM2 (0.39) | GAAGRM2KDM4E | |
| SCHEMBL14172120 | 0.80 | PIK3C3 (0.37) | POLBKDM4E | |
| SCHEMBL14218347 | 0.79 | SMN1; SMN2 (0.48) | SMN1; SMN2MAPK1TSHR | |
| SCHEMBL14218316 | 0.79 | SMN1; SMN2 (0.48) | SMN1; SMN2MAPK1TSHR |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 1 patent. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20100009957-A1 | NOVEL INHIBITORS OF BETA-LACTAMASE | MERCK SHARP & DOHME CORP. | 2010-01-14 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20100009957-A1 | NOVEL INHIBITORS OF BETA-LACTAMASE | MGAM, SI, MGAM2 | SMN1; SMN2 3397/4885MAPK1 3643/4885GAA 14/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.